We are live on
!
Find out more
MG
Meditor Group Portfolio holdings
AUM
$48.1M
1-Year Est. Return
38.67%
This Fund
S&P 500
This Quarter
Est. Return
+12.95%
1 Year Est. Return
+38.67%
3 Year Est. Return
+41.15%
5 Year Est. Return
+72.2%
10 Year Est. Return
+1,065.64%
AUM
$126M
AUM Growth
-$22.4M
(-15%)
Cap. Flow
-$21.1M
Cap. Flow
% of AUM
-16.82%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
2
Closed
–
Top Buys
No buys this quarter
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$20.8M |
| 2 |
ESPR
Esperion Therapeutics
ESPR
|
+$340K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.26% |
Similar funds
BHCM
VMV
BHH
LAMC
MAM
BCM
LOF
CLCM
Meditor Group's Q1 2023 Portfolio in Review
As of Q1 2023, Meditor Group held 4 positions worth $126M, down 15% from $148M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Meditor Group withdrew a net $21.1M in Q1 2023, reducing 2 holdings. Its largest reduction was Exelixis, cutting an estimated $20.8M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier.
- Meditor Group's biggest Q1 2023 reduction was Exelixis, cutting an estimated $20.8M.
- Meditor Group's ten largest holdings make up 100% of its $126M portfolio in Q1 2023.
- Meditor Group opened 0 new positions and closed 0 in Q1 2023.
- Meditor Group's portfolio value fell 15% quarter-over-quarter to $126M.
Based on Meditor Group's 13F filing for Q1 2023, filed 10 Apr 2023.